Biohaven epilepsy drug hits FDA hold nine days after SK Biopharma licensing deal
New CapabilitiesA rodent-metabolite finding freezes new enrollment in the drug's pivotal trials, splitting the programs's timeline
Today: Biohaven discloses hold;shares sink, timelines splitNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 1 hour agoNine days after Biohaven signed a licensing deal worth up to $795 million with SK Biopharmaceuticals for its epilepsy drug platform, the FDA halted new enrollment in the drug's two late-stage trials. The hold came not because BHV-7000 (opakalim) showed safety problems in humans—over 1,200 people have taken it and tolerability has been generally clean—but because a metabolite found in rat studies raised questions the agency couldn't fully assess. Biohaven says the finding's significance to people is uncertain and may be rodent-specific.
The split isfateful: BHV7000-303 (RISE 3), one of two pivotal trials in refractory focal epilepsy, finished enrolling in June and remains on track for top-line data in H2 2026. But BHV7000-302 (RISE 2), which had not yet completed recruitment, now sits frozen at new-patient entry, likely delaying its readout. Two weeks earlier, that same drug had been the centerpiece of a deal designed to share development costs with a deep-pocketed Korean licensee. Now the FDA's request for more nonclinical data—expected in the coming weeks—determines whether that deal's central asset limps or flies.
Why it matters
If the partial hold pushes BHV-7000 off schedule, Biohaven loses its main value driver and SK Biopharmaceuticals' $795M bet stalls—leaving both with few options.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
Organizations Involved
Neuroscience biotech developing opakalim (BHV-7000) for refractory focal epilepsy and other Kv7-targeting compoundshan.
Acquired exclusive worldwide rights to the Kv7 ion channel platform, including BHV-7000, nine days before FDA room.
Paused new enrollment in BHV-7000 trials requesting more nonclinical data ona rodent metabolite before proceeding.
Timeline
January 2024 September 2026
-
Biohaven discloses hold;shares sink, timelines split
Today MarketSEC filing and Reuters report;stock drops 13%+ premarket. RISE 3 unaffected, but RISE 2 enrollment stays paused, delaying its readout.
-
FDA issues partial clinical hold
RegulatoryAgency pauses new enrollment citing insufficient info on a rodent metabolite's potential human risk.Biohaven extends pause globally.
-
Biohaven licenses Kv7 platform to SK Biopharmaceuticals
CommercialSK gets worldwide rights including BHV-7000, valued at up to $795 million in upfront and milestones.
-
RISE 3 fully enrolled
ClinicalEnrollment completes in BHV7000-303,one of two pivotal trials,robo-pulsing dosing continues.
-
Troriluzole rejection forces R&D cuts
RegulatoryFDA turns away Biohaven's ataxia drug, prompting a 60% budget slash and a near-half stock collapse.
-
Biohaven clears FDA phase-2 gate
RegulatoryCompletes end-of-phase-2 meeting;advances BHV-7000 into two pivotal phase-3 focal epilepsy trials.
Historical Context
2 moments from history that rhyme with this story — and how they unfolded.
Sage Therapeutics' brexanolone (2017–2019)
Sage's postpartum-depression drug brexanolone hit an FDA clinical hold over a metabolite question yet despite initial data, the agency eventually approved it—two years later—after resubmission with additional safety analyses.
A two-year delay and added trial costs pushed Sage deep intoins the red, forcing equity raises.
The drug reached market on the strength of the original efficacy data, but its launch stalled on reimbursement and route-of-administration issues;Sage later restructured around newer CNS assets.
Shows unmetabolite-relatedholds can resolve without killing a drug—but they still cost years and large sums, which is exactly what BHV-7000's partners hope to avoid.
Intercept Pharmaceuticals' Ocaliva (2019–2020)
FDA issued a complete-response letter then a clinical hold on Intercept's NASH drug obeticholic acid over a drug-induced liver-injury signal,and subsequent data failed to win approval, eventuallydooming the program.
Intercept's shares lost roughly 80% of value within a year,and the company abandonedthe NASH indication.
The case became a cautionary tale about how regulator-requested safety analyses, whenunfavorable, can torpedo even late-stage programs.
Contrast scenario:if Biohaven's rodent-metabolite data come back inconclusive or worse, a similar fate awaits—making the upcoming nonclinical results existential,not a formality.
